0001209191-19-055543.txt : 20191106
0001209191-19-055543.hdr.sgml : 20191106
20191106172707
ACCESSION NUMBER: 0001209191-19-055543
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191106
FILED AS OF DATE: 20191106
DATE AS OF CHANGE: 20191106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Novo Holdings A/S
CENTRAL INDEX KEY: 0001388325
STATE OF INCORPORATION: G7
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39114
FILM NUMBER: 191197378
BUSINESS ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
BUSINESS PHONE: 45 8824 8824
MAIL ADDRESS:
STREET 1: TUBORG HAVNEVEJ 19
CITY: HELLERUP
STATE: G7
ZIP: 2900
FORMER NAME:
FORMER CONFORMED NAME: Novo A/S
DATE OF NAME CHANGE: 20070130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Galera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001563577
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461454898
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 LINDENWOOD DRIVE
STREET 2: SUITE 405
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: 610-725-1500
MAIL ADDRESS:
STREET 1: 101 LINDENWOOD DRIVE
STREET 2: SUITE 405
CITY: MALVERN
STATE: PA
ZIP: 19355
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2019-11-06
0
0001563577
Galera Therapeutics, Inc.
GRTX
0001388325
Novo Holdings A/S
TUBORG HAVNEVEJ 19
HELLERUP
G7
2900
DENMARK
0
0
1
1
SEE REMARKS
SERIES B PREFERRED STOCK
COMMON STOCK
2373152
D
SERIES C PREFERRED STOCK
COMMON STOCK
535869
D
Each share of Series B Preferred Stock and Series C Preferred Stock will automatically convert into shares of Common Stock upon the completion of the Issuer's initial public offering, in accordance with the applicable conversion ratio, resulting in the acquisition of the number of shares of common stock shown. There is no expiration date for the preferred stock.
Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
2019-11-06